Russell Investments Group’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $53.4K | Buy |
+14,234
| New | +$54.3K | ﹤0.01% | 3610 |
|
|
2025
Q2 | – | Sell |
-44,576
| Closed | -$28.3K | – | 3864 |
|
|
2025
Q1 | $28.3K | Buy |
44,576
+10,522
| +31% | +$8.16K | ﹤0.01% | 3035 |
|
|
2024
Q4 | $35.1K | Sell |
34,054
-13,595
| -29% | -$14.6K | ﹤0.01% | 2899 |
|
|
2024
Q3 | $56.2K | Buy |
47,649
+4,835
| +11% | +$6.14K | ﹤0.01% | 2766 |
|
|
2024
Q2 | $52.2K | Buy |
42,814
+16
| +0% | +$32 | ﹤0.01% | 2755 |
|
|
2024
Q1 | $93.3K | Buy |
42,798
+1,073
| +3% | +$1.98K | ﹤0.01% | 2584 |
|
|
2023
Q4 | $64.7K | Sell |
41,725
-3,901
| -9% | -$5.13K | ﹤0.01% | 2611 |
|
|
2023
Q3 | $58.9K | Sell |
45,626
-8,079
| -15% | -$12.7K | ﹤0.01% | 2727 |
|
|
2023
Q2 | $92.4K | Sell |
53,705
-3,350
| -6% | -$5.56K | ﹤0.01% | 2619 |
|
|
2023
Q1 | $86.2K | Sell |
57,055
-1,192
| -2% | -$2.69K | ﹤0.01% | 2616 |
|
|
2022
Q4 | $93.2K | Sell |
58,247
-3,073
| -5% | -$4.55K | ﹤0.01% | 2682 |
|
|
2022
Q3 | $88K | Sell |
61,320
-174,150
| -74% | -$268K | ﹤0.01% | 2688 |
|
|
2022
Q2 | $429K | Buy |
235,470
+150,091
| +176% | +$287K | ﹤0.01% | 2318 |
|
|
2022
Q1 | $227K | Sell |
85,379
-45,672
| -35% | -$175K | ﹤0.01% | 2434 |
|
|
2021
Q4 | $567K | Sell |
131,051
-35,359
| -21% | -$207K | ﹤0.01% | 2398 |
|
|
2021
Q3 | $846K | Sell |
166,410
-2,053
| -1% | -$11K | ﹤0.01% | 2261 |
|
|
2021
Q2 | $1.06M | Sell |
168,463
-16,045
| -9% | -$125K | ﹤0.01% | 2281 |
|
|
2021
Q1 | $1.42M | Sell |
184,508
-43,734
| -19% | -$346K | ﹤0.01% | 2081 |
|
|
2020
Q4 | $1.5M | Sell |
228,242
-259,428
| -53% | -$1.85M | ﹤0.01% | 1910 |
|
|
2020
Q3 | $3.24M | Buy |
487,670
+384,490
| +373% | +$2.85M | 0.01% | 1394 |
|
|
2020
Q2 | $857K | Buy |
103,180
+9,202
| +10% | +$85.5K | ﹤0.01% | 2140 |
|
|
2020
Q1 | $718K | Buy |
93,978
+50,084
| +114% | +$349K | ﹤0.01% | 2006 |
|
|
2019
Q4 | $363K | Buy |
+43,894
| New | +$296K | ﹤0.01% | 2512 |
|
|
2018
Q4 | – | Sell |
-25,248
| Closed | -$467K | – | 2935 |
|
|
2018
Q3 | $467K | Sell |
25,248
-101,571
| -80% | -$2.31M | ﹤0.01% | 2418 |
|
|
2018
Q2 | $2.9M | Sell |
126,819
-64,382
| -34% | -$1.64M | 0.01% | 1559 |
|
|
2018
Q1 | $5.44M | Buy |
191,201
+83,448
| +77% | +$2.38M | 0.01% | 1324 |
|
|
2017
Q4 | $2.38M | Buy |
107,753
+92,305
| +598% | +$1.91M | ﹤0.01% | 1735 |
|
|
2017
Q3 | $281K | Sell |
15,448
-6,686
| -30% | -$104K | ﹤0.01% | 2603 |
|
|
2017
Q2 | $343K | Buy |
22,134
+292
| +1% | +$4.4K | ﹤0.01% | 2548 |
|
|
2017
Q1 | $377K | Hold |
21,842
| – | – | ﹤0.01% | 2530 |
|
|
2016
Q4 | $243K | Buy |
+21,842
| New | +$265K | ﹤0.01% | 2669 |
|
Other funds holding CTMX
KCM
PA
VA
Russell Investments Group's CTMX Position: Q2 2026 in Review
Russell Investments Group opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 14,234 shares worth $53.4K. The stake represents ﹤0.01% of the portfolio and ranks #3610 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in CTMX as recently as Q1 2025.
Russell Investments Group first reported a position in CTMX in Q4 2016 and has held it in 31 quarters since. The position peaked at $5.44M in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.
- Russell Investments Group held 14,234 shares of CytomX Therapeutics worth $53.4K as of Q2 2026.
- CytomX Therapeutics was a new Russell Investments Group position in Q2 2026.
- CytomX Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3610 holding.
- Russell Investments Group first reported a position in CytomX Therapeutics in Q4 2016 and has held it in 31 quarters since.
- Russell Investments Group's CytomX Therapeutics position peaked at $5.44M in Q1 2018.
- 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.
Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.